Literature DB >> 454151

The expanded polytetrafluoroethylene graft. Three years' experience with 362 grafts.

H Haimov, F Giron, J H Jacobson.   

Abstract

A total of 362 polytetrafluoroethylene (PTFE) grafts were implanted in patients as vascular substitutes in a variety of vascular reconstructive procedures. A total of 184 were used in femoropopliteal bypass operations. Cumulative patency rates showed 74% patency at the end of the first year of observation and 58% after two and three years. Seventeen grafts were used for femorotibial bypasses, with a cumulative patency rate of 40.4% after one year. Ninety-eight grafts were implanted in the upper or lower extremity to serve as vascular access for hemodialysis. For this group, the cumulative one-year patency rate was 83%. Sixty-three additional grafts were implanted in various other anatomic locations. Based on this experience, the PTFE graft seems to be a promising and versatile vascular prosthesis, although it should be used cautiously.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 454151     DOI: 10.1001/archsurg.1979.01370300027003

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Linton patch angioplasty. An adjunct to distal bypass with polytetrafluoroethylene grafts.

Authors:  R C Batson; V S Sottiurai; C C Craighead
Journal:  Ann Surg       Date:  1984-06       Impact factor: 12.969

2.  Seven-year follow-up of expanded polytetrafluoroethylene (PTFE) femoropopliteal bypass grafts.

Authors:  C E McAuley; D L Steed; M W Webster
Journal:  Ann Surg       Date:  1984-01       Impact factor: 12.969

3.  Early experience with a new PTFE graft below the inguinal ligament.

Authors:  J M Duncan; G J Reul; W Aronski; G L Hallman; D A Cooley
Journal:  Tex Heart Inst J       Date:  1987-06

4.  Antiplatelet therapy reduces aortic intimal hyperplasia distal to small diameter vascular prostheses (PTFE) in nonhuman primates.

Authors:  P O Hagen; Z G Wang; E M Mikat; D B Hackel
Journal:  Ann Surg       Date:  1982-03       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.